ElitechGroup Mdx is pleased to announce that ELIVERSE will be launched in Europe in 2024.
With its introduction, ELITechGroup will have launched three molecular sample-to-result platforms in 8 years.

Read the press release here.

Copenhagen, 15th April 2023 – At the ECCMID congress ELITech Group unveiled the upcoming launch of a new high throughput sample-to-result instrument for molecular diagnostics.

In 2016 ELITechGroup introduced ELITe InGenius, its first sample-to-result system for molecular diagnostics. Since then, the company has been expanding the system’s menu to more than 50 CE-IVD parameters and has validated more than 20 sample matrices. BeGenius was launched in 2021 to address the needs of laboratories that require higher throughput.
To date, more than 1100 InGenius and BeGenius instruments have been installed across the globe. Users appreciate the broad menu as well as the instrument’s versatility and robustness.
Elitech MDx is committed to transitioning its complete portfolio of CE-IVD parameters to IVDR and has already received the first IVDR certificates for both InGenius and BeGenius.

The company’s new high throughput system will be based on ELITech’s proven extraction and assay technology. It will use the same reagents as InGenius and BeGenius. The instrument offers continuous loading of samples and reagents coupled with real random-access capability. The user will be able to run in parallel different PCR reagents, protocols, and sample matrices, with maximum versatility.
ELITech’s broad and expanding menu of IVD assays together with the instrument’s superior throughput and multiplexing capability will make it the ideal platform for laboratories with a high level of complexity in their routine testing.
The European launch of the new system is planned for the end of 2024.

With the introduction of its high throughput system, ELITechGroup will have launched three molecular sample-to-result platforms in 8 years. This track record demonstrates the company’s commitment to serving molecular laboratories worldwide with innovative instruments and state-of-the-art PCR assays – independent of their throughput needs.

About ELITech Group

ELITech Group is an integrated in-vitro diagnostics company that serves hospitals and diagnostic laboratories in more than 100 countries. The company develops, manufactures, and markets a wide range of diagnostic products and solutions – instruments, reagents, and software.

ELITech Molecular Diagnostics (MDx), one of the four business units of ELITech Group, serves the needs of clinical and research laboratories by offering a wide range of molecular diagnostic products, including more than 50 CE-IVD assays and instruments as well as software applications.

Turin, 22nd December 2022 – ELITechGroup has inaugurated its new headquarters in Turin, becoming one of the largest molecular biology hubs in Europe.

The inauguration was held on Friday 16th December in the presence of institutional figures, collaborators, and employees.

At the ribbon cutting, Michela Favaro – Deputy Mayor of Turin – and Roberto Meda – ELITechGroup’s Senior Vice President responsible for Molecular Diagnostics.

The company, founded 30 years ago as a spin-off of the University of Turin, has established itself in the field of molecular biology moving from a local to a multinational reality.

“We are proud to inaugurate this new headquarters – said Roberto Meda – ELITechGroup’s Senior Vice President responsible for Molecular Diagnostics – It has been possible thanks to the company’s top-level scientific expertise, managerial courage, passion, and propensity for innovation. These have been the steps behind the strategic investments, which, together with the extraordinary human and professional qualities of the women and men in our company, have enabled us to achieve exceptional results, thus becoming a reference centre for molecular biology worldwide. A larger and more innovative hub where we will be able to better experience the company, with its new and modern spaces designed for a new social networking.”

About ELITechGroup

ELITechGroup is a privately held group of worldwide manufacturers and distributors of in vitro diagnostic equipment and reagents. By bringing together IVD specialty companies that offer innovative products and solutions, ELITechGroup has become a major contributor in advancing clinical diagnostics to laboratories in the proximity market, those operating closer to the patient.

Other clinical conditions that may impact serum Cholinesterase activity are acute and chronic liver disease, inflammation, malnutrition, and Alzheimer’s disease. Also, exposure to pesticides containing organophosphates or any other deliberate or unintended exposure to organophosphates may affect Cholinesterase in serum. Organophosphates bind and inhibit cholinesterase activity affecting the peripheral and central nervous system.

Cholinesterase hydrolyses choline esters and there are two types: Acetylcholinesterase and Pseudocholinesterase. They are distinguished from each other based on the preferred substrate: Acetylcholine or Butyrylcholine. Pseudocholinesterase is found predominantly in the liver but also in the pancreas, intestine, heart, and brain, and it’s present in serum/plasma. Acetylcholinesterase is found in red blood cells and nervous tissue.

A number of methods utilizing a range of detection technologies have been developed for estimating serum/plasma Cholinesterase activity, however, many of these are not so well suited to routine use or require specialized equipment, which may not be readily available. The most common method used in routine clinical chemistry service laboratories is spectrometry, detecting thiocholine or other substrates (Ellman, Garry & Routh method or DGKC method).(2)

The ELITechGroup Clinical Chemistry Cholinesterase reagent is available as a common kit for Selectra systems. The Cholinesterase reagents are ready-to-use liquid stable, with 8 weeks of onboard stability (Selectra Pro & Mach series). The method is based on the DGKC published method and provides significantly better onboard reagent and calibration stability compared with commercial reagents utilizing the Ellman method. The calibration is traceable to DGKC method using the ELICAL calibrators. ELITechGroup Clinical Chemistry Cholinesterase reagents have an ideal shelf life and combined with optimized packaging, it offers an economical option for low-volume testing.

For more information: Clinical Chemistry Reagents Catalogue or contact sales.ecsnl@elitechgroup.com

1. https://rarediseases.info.nih.gov/diseases/7482/pseudocholinesterase-deficiency
2. S. Chowdhary et al. / Clinica Chimica Acta 431 (2014) 66–76
3. Photo by Anna Shvets: https://www.pexels.com/photo/anesthesia-mask-lying-in-an-operating-room-during-surgery-6291290/

Sunlight plays an essential role in Vitamin D production
Since skin exposure to sunlight (UV) plays an essential part in Vitamin D production, people who avoid exposure to the sun, have an increased risk of developing Vitamin D deficiency e.g. indoor occupations, housebound people, elderly in high care, or when skin is covered for religious or cultural reasons. Also, patients with signs, symptoms and/or planned treatment for various conditions might be at risk: (1) osteoporosis or osteomalacia, (2) increased alkaline phosphatase with otherwise normal LFTs, (3) hyperparathyroidism, hypo- or hypercalcemia, or hypophosphatemia, (4) malabsorption (i.e. CF, IBD & coeliac), (5) patients with medications known to decrease vitamin D levels (i.e. anticonvulsants) and (6) CRF and transplant recipients.

Forms of Vitamin D
There are two forms of vitamin D, D2, and D3. D3 (90%) is produced mainly photochemically in the skin when exposed to sunlight, and both D3 and D2 can also be sourced from diet or supplements. D2 and D3 are further hydroxylated in the liver to produce the prohormone 25 Hydroxyvitamin D3 (25-OHD). 25OHD is needed for the production of the active hormone 1,25-dihydroxyvitamin D3 (1,25D). 1,25D maintains the essential calcium balance in the body and is formed by hydroxylation of 25-OHD in the kidneys.

1,25D, the active form of vitamin D, has a very short half-life in the serum (T1/2 is 8 hours) and is highly regulated through parathyroid hormone (PTH). 25-OHD, the prohormone, on the other hand, has the highest affinity for vitamin D binding protein and highest concentration in the serum. 25-OHD is stable with a long half-life (T1/2 22-30 days) and is not affected by changes in PTH or Calcium. The prohormone 25-OHD is the metabolite that best assesses overall Vitamin D status; “Total 25-OHD” is the sum of 25-OHD3 + 25-OHD2.

ELITechGroup’s Vitamin D reagent
ELITechGroup Clinical Chemistry vitamin D reagent measures “Total 25-OHD” i.e. both D2 and D3 are measured equally. It is a particle-enhanced (Latex) immunoturbidimetric assay (PEITA) that enables routine Vitamin D testing to be performed on a standard clinical chemistry system like Selectra. The PEITA Vitamin D method doesn’t require specialized equipment or operators like LC-MS/MS, and improves laboratories’ efficiency in workflow compared to ELISA assays. The method is traceable to international standards (calibrators and trueness control traceable to SRM972) and benchmarked against LC-MS/MS gold standard reference method. It’s certified by CDC Vitamin D standardization Certification program (VDSCP), and also meets the criteria set by DEQAS advisory panel. Further, the assay is USA FDA 510(k) approved, USA CLIA classified and CE-IVD certified.

ELITechGroup Clinical Chemistry Vitamin D reagents are ready-to-use liquid stable with a broad measuring range and 28 days on board reagent stability. Additional to the short turnaround time (<10 minutes) compared with CLIA methods, there’s no requirement to dilute high samples or use additional collection tubes which provide cost and workflow efficiency to the laboratory.

For more information: Clinical Chemistry Reagents Catalogue or contact sales.ecsnl@elitechgroup.com